Article
Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Sept 2012
Vermehren Johannes, Susser Simone, Berger Annemarie, Perner Dany, Peiffer Kai-Henrik, Allwinn Regina, Zeuzem Stefan, Sarrazin Christoph
Abstract excerpt
BACKGROUND: Virologic response-monitoring is essential for determining therapy duration in patients with chronic hepatitis C virus (HCV) infection. This is usually performed using highly sensitive HCV-RNA assays. However, HCV-RNA assays are time-consuming, expensive and require highly trained personnel. Quantitative determination of HCV core-antigen (HCVAg) levels may be used to supplement treatment monitoring....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
